Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01835158
Recruitment Status : Active, not recruiting
First Posted : April 18, 2013
Last Update Posted : March 23, 2018
Information provided by (Responsible Party):
National Cancer Institute (NCI)